

## **GENENTA TO PRESENT UPDATED PHASE I/II DATA AT UPCOMING SCIENTIFIC CONGRESSES SNO AND ASH**

November 16, 2021

MILAN (Italy)/NEW YORK (NY, USA) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that it will be presenting updated preliminary Phase I/II clinical data on Temferon at two upcoming scientific congresses.

### **The Society for Neuro-Oncology (SNO) 2021 Annual Meeting and Education Day, November 18-21, Boston, USA**

Title: TEM-GBM: A Phase I-IIa Dose-Escalation Study Delivering IFN- $\alpha$  within Glioblastoma Multiforme Tumor Microenvironment by Genetically Modified TIE-2 Expressing Monocytes

Type: Poster presentation

Time: Friday November 19, 2021, 7.30 PM – 9.30 PM ET

### **63rd American Society of Hematology (ASH) Annual Meeting and Exposition 2021, December 11-14, Atlanta, USA and virtual**

Title: TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN- $\alpha$  within Glioblastoma Tumor Microenvironment

Type: Poster presentation

Day: Sunday December 12, 2021, 6 PM – 8 PM ET

#### **About Genenta Science**

Genenta ([www.genenta.com](http://www.genenta.com)) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.



**GENENTA SCIENCE S.p.A.**

Via Olgettina, 58 - 20132 Milano (Italy) - [genentascience@legalmail.it](mailto:genentascience@legalmail.it) - [www.genenta.com](http://www.genenta.com)  
cf e P. Iva 08738490963 - REA 2045555 - Cap. Sociale Euro 50.000,00

#### **Investor Relations - LifeSci Advisors**

Mary-Ann Chang, CFA  
+44 7483 28 48 53  
[mchang@lifesciadvisors.com](mailto:mchang@lifesciadvisors.com)

#### **Genenta Media/Investor Contact**

Stefania Mazzoleni, PhD  
+39 339 709 59 31  
[stefania.mazzoleni@genenta.com](mailto:stefania.mazzoleni@genenta.com)